ICECURE MEDICAL LTD (ICCM)
IL0011224156 - Common Stock
ICECURE MEDICAL LTD
NASDAQ:ICCM (6/14/2024, 7:15:12 PM)
After market: 0.782 -0.04 (-4.52%)0.819
+0.06 (+7.76%)
Company Profile
IceCure Medical Ltd. is a commercial stage medical device company. The firm operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Company Info
ICECURE MEDICAL LTD
7 Ha'eshel St., PO Box 3163
CAESAREA
P: 97246230333
CEO: EYAL SHAMIR
Employees: 65
Website: https://icecure-medical.com/
ICCM News
4 days ago - IceCure MedicalPositive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal FunctionICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors with 89.5% recurrence-free rate...
12 days ago - IceCure MedicalFDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness PlanDemonstrates public health importance of assessing ProSense®'s potential to offer optimal treatment that benefits women with early-stage breast cancer...
18 days ago - InvestorPlaceICCM Stock Earnings: Icecure Medical Meets EPS, Misses Revenue for Q1 2024ICCM stock results show that Icecure Medical met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
26 days ago - IceCure MedicalIceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation...
a month ago - IceCure MedicalIceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation...
a month ago - IceCure MedicalIndependent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation...
ICCM Twits
Here you can normally see the latest stock twits on ICCM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
